Skip to main content
RESMED INC logo

RESMED INC — Investor Relations & Filings

Ticker · RMD LEI · 254900O2VD7IQ5OGI615 ASX Manufacturing
Open in API
Filings indexed 1,641 across all filing types
Latest filing 2023-02-02 Share Issue/Capital Cha…
Country AU Australia
Listing ASX RMD

About RESMED INC

https://www.resmed.com

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s primary product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel machines, and a variety of masks and accessories designed to improve patient adherence and comfort. ResMed distinguishes itself through its focus on digital health, offering integrated software platforms that enable remote patient monitoring and data-driven clinical insights for healthcare providers. Additionally, the company provides software-as-a-service (SaaS) solutions to support out-of-hospital care settings, including home health, hospice, and skilled nursing facilities, aiming to improve patient outcomes and reduce overall healthcare costs.

Recent filings

Filing Released Lang Actions
Statement of CDIs on issue - RMD 4 pages 23.0KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Statement of CDIs on Issue' and contains detailed information about the number and class of CHESS Depositary Interests (CDIs) and other securities on issue for ResMed Inc. It includes monthly data for January 2023, net differences in securities issued, and reasons for changes such as transfers and new shares issued under employee plans. The document is relatively short (3091 characters) and focuses on securities issued and changes in share capital rather than financial performance, management changes, or voting results. This matches the description of a Share Issue/Capital Change announcement, which covers new share issues, stock splits, or other capital changes. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2023-02-02 English
FORM 10Q for Qtr ended December, 2022 42 pages 309.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and explicitly states it is a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934' for the quarterly period ended December 31, 2022. It contains detailed financial statements including balance sheets, statements of operations, comprehensive income, changes in equity, and notes to the financial statements. The length of the document is substantial (15,000 characters), and it includes substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). Therefore, this document is a comprehensive quarterly financial report, fitting the definition of an Interim / Quarterly Report (IR). Q2 2023
2023-01-29 English
ResMed Announces Results for the Second Quarter of FY2023 10 pages 339.9KB
Earnings Release Classification · 95% confidence The document is titled 'ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023' and contains detailed financial data including revenue, gross margin, income from operations, net income, earnings per share, and balance sheets for the quarter ended December 31, 2022. It includes both GAAP and non-GAAP financial measures, operational highlights, and a discussion of results compared to prior periods. The document also references a webcast of the earnings call and provides a safe harbor statement typical of earnings releases. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content is consistent with a quarterly earnings release providing initial financial results and highlights for the period, not a full annual report or management discussion. Therefore, the document is best classified as an Earnings Release (ER). Q2 2023
2023-01-26 English
Chairman Appointment/Resignation 2 pages 169.8KB
Board/Management Information Classification · 95% confidence The document is a press release announcing a change in the company's board of directors, specifically the appointment of Michael Farrell as Chair of the Board and Peter Farrell becoming Chair Emeritus. It focuses on management and board leadership changes without financial data or report content. There is no indication of financial results, audit information, or regulatory filings. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3825 characters, which is consistent with a typical announcement rather than a full report.
2023-01-26 English
Dividend/Distribution - RMD 4 pages 25.4KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Notification of dividend / distribution' and contains detailed information about dividend amount, ex-date, record date, payment date, currency, withholding tax rate, and other dividend-related specifics. It is an announcement of dividend payment details rather than a full financial report or earnings release. The document length is 4503 characters, which is relatively short and focused solely on dividend information. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2023-01-26 English
RMD to Report Second Quarter Fiscal 2023 Results 1
Regulatory Filings Classification · 95% confidence The document is a short announcement (2241 characters) stating that ResMed will report its second quarter fiscal 2023 earnings on January 26, 2023, after market close. It includes details about a webcast and replay information for the earnings call. There is no actual financial data or detailed results presented in this document. It is clearly an announcement of an upcoming earnings release and webcast, not the earnings release itself or a transcript. According to the rules, such announcements are best classified as Earnings Release (ER) announcements if they contain key highlights, but this document contains no financial highlights, only the announcement of the date and webcast details. Therefore, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about the timing of the earnings release and webcast, without substantive financial content or results. Confidence is high due to clear identification of the document as an earnings announcement without financial data.
2023-01-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.